Welcome to our dedicated page for Brainstorm Cell Therapeutics I news (Ticker: BCLI), a resource for investors and traders seeking the latest updates and insights on Brainstorm Cell Therapeutics I stock.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) delivers innovative autologous stem cell therapies targeting neurodegenerative diseases through its NurOwn® platform. This dedicated news hub provides investors and healthcare stakeholders with timely updates on clinical developments, regulatory progress, and strategic initiatives.
Access authoritative reporting on key milestones including clinical trial results, FDA communications, manufacturing partnerships, and scientific presentations. Our curated news collection enables efficient tracking of BCLI's progress in advancing treatments for ALS, multiple sclerosis, and Parkinson's disease.
Key content categories include:
- Clinical trial phase updates
- Regulatory submissions and designations
- Research collaborations
- Peer-reviewed publication highlights
- Financial reporting
Bookmark this page for consolidated access to verified BCLI developments. Check regularly for updates on novel cellular therapies addressing critical unmet medical needs in neurology.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced that Dr. Ralph Kern will present a corporate overview at the 40th Annual Canaccord Genuity Growth Conference, held virtually from August 11-13, 2020. One-on-one meetings with institutional investors will also be available on the presentation day. The event will take place on August 13, 2020, at 3:30 PM ET, with a webcast accessible for viewing. BrainStorm develops adult stem cell therapies, notably its MSC-NTF cells for ALS, which have received Orphan Drug status from the FDA and EMA. Phase 3 trials are ongoing, aiming for FDA approval.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) reported its Q2 2020 financial results, highlighting a net loss of $7.39 million, up from $4.90 million in Q2 2019. Despite COVID-19 challenges, the firm completed enrollment in its Phase 3 ALS trial, with data expected by November 2020. BCLI is also advancing its NurOwn platform into new areas, including Alzheimer's, with a Phase 2 trial planned in Europe. The company has approximately $37.5 million in available funding as of July 31, 2020, reflecting growth from prior periods.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) will hold a conference call on August 5, 2020, at 8:00 a.m. EDT to update shareholders on its Q2 financial results and provide corporate updates. CEO Chaim Lebovits will discuss the timeline for the Phase 3 trial of NurOwn® in ALS while Dr. Revital Aricha will cover recent advancements in R&D, including a preclinical study on COVID-19 treatment. The company has recently completed enrollment for its pivotal ALS trial and received FDA clearance for a Phase 2 trial in progressive MS.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced progress in its development of an innovative exosome-based platform technology targeting severe COVID-19 infection. Key findings from a mouse model study showed that intratracheal administration of exosomes derived from MSCs using NurOwn® technology led to significant improvements in lung parameters, including functional recovery and reduced lung damage. The company plans to discuss the results during its Q2 earnings call on August 5 and is considering a clinical trial for ARDS based on these promising preclinical results.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) is hosting a Key Opinion Leader webinar regarding its Alzheimer's Disease (AD) program today at 8:15 AM ET. The company is expanding its clinical pipeline to develop NurOwn and is initiating a Phase 2 study in AD. This 52-week, open-label trial will evaluate NurOwn in 40 participants with prodromal to mild AD at leading medical centers in the Netherlands and France. The webinar features insights from prominent researchers, aiming to provide an overview of the trial's goals and implications for Alzheimer's treatment.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) completed participant dosing in its Phase 3 trial of NurOwn® for amyotrophic lateral sclerosis (ALS). Approximately 200 participants received either MSC-NTF cells or a placebo over four months. The company anticipates top-line data by Q4 2020, aligning with their enrollment timeline. CEO Chaim Lebovits emphasized this milestone's importance for a potential Biologics License Application. The trial is being conducted at six renowned medical centers, and the company has a recent FDA clearance for a Phase 2 trial in progressive multiple sclerosis.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) will host a KOL webinar on its Alzheimer's disease clinical program on July 8, 2020, at 8:15 AM ET. The webinar will feature presentations from Dr. Philip Scheltens and Dr. Bruno Dubois, lead investigators of a Phase 2 trial assessing NurOwn® in 40 participants with prodromal to mild AD. The trial aims to evaluate the efficacy of autologous MSC-NTF cells, designed to deliver neurotrophic factors targeting neurodegenerative disorders. BrainStorm's expansion into Alzheimer's comes after successful developments in ALS and progressive multiple sclerosis.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) has announced a new clinical program to develop NurOwn for treating Alzheimer's disease. A multi-national Phase 2 clinical trial is planned to evaluate the safety and efficacy of NurOwn in patients with prodromal to mild Alzheimer's. The trial will include 40 participants receiving three doses over 52 weeks. The company aims to build on its existing ALS program and believes NurOwn can potentially address various neurodegenerative disorders.
BrainStorm Cell Therapeutics (BCLI) announced its inclusion in the Russell 2000® and Russell 3000® Indexes effective June 29, 2020. This addition is significant as it reflects BrainStorm’s market capitalization and positions the company for greater visibility and investment opportunities. The Russell Indexes are widely used by investment managers and institutional investors, with approximately $9 trillion in assets benchmarked against these indexes.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) reported its Q1 2020 financial results and provided updates on clinical trials amid the COVID-19 pandemic. The Phase 3 ALS trial is on track for Q4 2020 data readout, with patient treatments ongoing. The company signed an agreement for EMEA regulatory guidance and leased a facility in Tel Aviv to enhance manufacturing capacity. Despite challenges, cash reserves increased to $14.5 million but net losses widened to $8.1 million, compared to $5.03 million in Q1 2019.